Search in:

Journal of Market Access & Health Policy Volume 3, 2015 - Issue 1

Journal homepage

Open access

596

Views

CrossRef citations to date

Altmetric

Original Research Articles

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab

Xavier RoblinDepartment of GastroenterologyUniversity Hospital of Saint Etienne, Saint-Etienne, France

, MD,

Alain AttarDepartment of GastroenterologyIBD, Nutritional Support, Hôpital Beaujon, Clichy, France

, MD, PhD,

Michel LamureUniversity Claude Bernard Lyon 1, Lyon, FranceCorrespondence[email protected]

, PhD,

Bernard Savarieau Nukleus Paris, France

, MD,

Pierre BrunelPharmacy DepartmentUniversity Hospital of Saint Etienne, Saint-Etienne, France

Gérard DuruUniversity Claude Bernard Lyon 1, Lyon, France

, PhD &

Laurent Peyrin-BirouletInserm U954 and Department of GastroenterologyUniversité de Lorraine, Nancy, France

, MD, PhD show all

Article: 29229 | Received 22 Jul 2015, Accepted 23 Sep 2015, Published online: 30 Oct 2015

Cite this article
https://doi.org/10.3402/jmahp.v3.29229
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (12)

Silvia Marquez-Megias, Ricardo Nalda-Molina, Javier Sanz-Valero, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix & Amelia Ramon-Lopez. (2022) Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics 14:5, pages 1009.
Crossref

Byron P. Vaughn. (2021) A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. Journal of Clinical Medicine 10:21, pages 4990.
Crossref

Jiaqi Yao, Xinchan Jiang & Joyce H S You. (2021) Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis. Journal of Gastroenterology and Hepatology 36:9, pages 2397-2407.
Crossref

Jiaqi Yao, Xinchan Jiang & Joyce H S You. (2021) A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy. Inflammatory Bowel Diseases 27:2, pages 275-282.
Crossref

Aurélie Truffot, Jean-François Jourdil, Barbara Seitz-Polski, Paolo Malvezzi, Vesna Brglez, Françoise Stanke-Labesque & Elodie Gautier-Veyret. (2021) Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clinical Biochemistry 87, pages 60-66.
Crossref

Richard P McNeill & Murray L Barclay. (2020) Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology 55, pages 41-46.
Crossref

Abhinav Vasudevan, Peter R Gibson & Daniel R Van Langenberg. (2019) Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:9, pages 1462-1473.
Crossref

Jean Lawton, Hamza Achit, Lieven Pouillon, Emmanuelle Boschetti, Béatrice Demore, Thierry Matton, Charlène Tournier, Martin Prodel, Laurent Peyrin-Biroulet & Francis Guillemin. (2019) Cost‐of‐illness of inflammatory bowel disease patients treated with anti‐tumour necrosis factor: A French large single‐centre experience. United European Gastroenterology Journal 7:7, pages 908-913.
Crossref

Nicholas Carman, David R. Mack & Eric I. Benchimol. (2018) Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports 20:5.
Crossref

M. Anthony Sofia & David T. Rubin. (2017) The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Digestive Diseases and Sciences 62:4, pages 833-842.
Crossref

Giovanni C Actis & Rinaldo Pellicano. (2017) Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World Journal of Gastrointestinal Pharmacology and Therapeutics 8:2, pages 114.
Crossref

Laura Martelli, Pablo Olivera, Xavier Roblin, Alain Attar & Laurent Peyrin-Biroulet. (2016) Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. Journal of Gastroenterology 52:1, pages 19-25.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab

Articles from other publishers (12)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab

Citations (12)

Articles from other publishers (12)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date